Ishani Dasgupta
Senior Scientist AbbVie
Ishani Dasgupta is a Senior Scientist in Immunology Discovery at AbbVie. Her work focuses on early-stage target discovery for autoimmune diseases, using CRISPR-based screening and gene editing approaches to identify and validate novel therapeutic targets. She leads efforts to characterize target biology and assess their potential for drug development, supporting progression from discovery through preclinical stages. Her research also spans in vivo gene editing technologies and emerging cell therapies, contributing to the advancement of innovative treatments within AbbVie’s immunology portfolio.
Seminars
Tuesday 29th September 2026
Leveraging CRISPR Arrayed Screens to Validate & De-Risk Targets Through Off-Target Reduction
10:00 am
- Exploring how CRISPR arrayed screens can be designed and deployed to identify and validate novel targets, giving you a scalable framework for accelerating early discovery
- Examining how validated CRISPR screen hits are assessed for pipeline fit across autoimmune disease indications, helping you strengthen your own target selection criteria
- Discussing strategies to minimize off-target effects during target identification screening, equipping you with optimized guide RNA and high-fidelity Cas9 approaches to improve hit confidence
